TY - JOUR
T1 - Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism
T2 - A Population-Based Study
AU - Savica, Rodolfo
AU - Turcano, Pierpaolo
AU - Bower, James H.
AU - Ahlskog, J. Eric
AU - Mielke, Michelle M.
N1 - Funding Information:
Grant Support: This study was supported by award R01 AG034676 from the National Institute on Aging of the National Institutes of Health and by the Mayo Foundation for Medical Education and Research. The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Grant Support: This study was supported by award R01 AG034676 from the National Institute on Aging of the National Institutes of Health and by the Mayo Foundation for Medical Education and Research. The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Potential Competing Interests: Dr Savica receives funding from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Parkinson's Disease Foundation, Inc and unrestricted research grants from Acadia Pharmaceuticals Inc. Dr Bower receives funding from the Parkinson's Foundation. Dr Ahlskog receives royalties from Oxford University Press for 3 recently published books. Dr Mielke receives funding from the National Institutes of Health and unrestricted research grants from Biogen Inc and H. Lundbeck A/S and has consulted for Lysosomal Therapeutics, Inc and Eli Lilly and Company. Dr Turcano has no disclosures. The authors thank Lea C. Dacy for formatting and editing support. Grant Support: This study was supported by award R01 AG034676 from the National Institute on Aging of the National Institutes of Health and by the Mayo Foundation for Medical Education and Research. The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Potential Competing Interests: Dr Savica receives funding from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Parkinson's Disease Foundation, Inc and unrestricted research grants from Acadia Pharmaceuticals Inc. Dr Bower receives funding from the Parkinson's Foundation. Dr Ahlskog receives royalties from Oxford University Press for 3 recently published books. Dr Mielke receives funding from the National Institutes of Health and unrestricted research grants from Biogen Inc and H. Lundbeck A/S and has consulted for Lysosomal Therapeutics, Inc and Eli Lilly and Company. Dr Turcano has no disclosures.
Publisher Copyright:
© 2019
PY - 2019/9
Y1 - 2019/9
N2 - Objective: To compare survival by the presenting parkinsonism symptoms at diagnosis among patients with incident clinically diagnosed synucleinopathies. Patients and Methods: Using the Rochester Epidemiology Project medical records–linkage system, we identified all persons residing in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from January 1, 1991, through December 31, 2010. A movement disorder specialist reviewed the complete medical records of each individual to confirm the presence of parkinsonism, determine the type of synucleinopathy, and identify the onset dates of each cardinal symptom (tremor at rest, bradykinesia, rigidity, and impaired postural reflexes). We determined the median time from age at diagnosis to death or censoring (June 30, 2015) for each presenting symptom and the age- and sex-adjusted risk of death. Results: From 1991 through 2010, a total of 433 individuals had a synucleinopathy diagnosed (301 [69.5%], Parkinson disease; 68 [15.7%], dementia with Lewy bodies; 52 [12.0%], Parkinson disease dementia; and 12 [2.8%], multiple systems atrophy with parkinsonism). Overall, the risk of death in the tremor-predominant group was less than that in the bradykinesia/rigidity-only group (hazard ratio [HR], 0.59; 95% CI, 0.40-0.87; P=.007). Similarly, risk of death in the bradykinesia/rigidity-only group was significantly greater than in the tremor-predominant group (HR, 1.75; 95% CI, 1.23-2.51; P=.002) and compared with tremor before bradykinesia (HR, 1.75; 95% CI, 1.24-2.47; P=.001). Conclusion: Patients with tremor as a presenting symptom have longer survival. In contrast, the presence of bradykinesia/rigidity as a presenting symptom correlates with reduced survival across all types of synucleinopathies.
AB - Objective: To compare survival by the presenting parkinsonism symptoms at diagnosis among patients with incident clinically diagnosed synucleinopathies. Patients and Methods: Using the Rochester Epidemiology Project medical records–linkage system, we identified all persons residing in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from January 1, 1991, through December 31, 2010. A movement disorder specialist reviewed the complete medical records of each individual to confirm the presence of parkinsonism, determine the type of synucleinopathy, and identify the onset dates of each cardinal symptom (tremor at rest, bradykinesia, rigidity, and impaired postural reflexes). We determined the median time from age at diagnosis to death or censoring (June 30, 2015) for each presenting symptom and the age- and sex-adjusted risk of death. Results: From 1991 through 2010, a total of 433 individuals had a synucleinopathy diagnosed (301 [69.5%], Parkinson disease; 68 [15.7%], dementia with Lewy bodies; 52 [12.0%], Parkinson disease dementia; and 12 [2.8%], multiple systems atrophy with parkinsonism). Overall, the risk of death in the tremor-predominant group was less than that in the bradykinesia/rigidity-only group (hazard ratio [HR], 0.59; 95% CI, 0.40-0.87; P=.007). Similarly, risk of death in the bradykinesia/rigidity-only group was significantly greater than in the tremor-predominant group (HR, 1.75; 95% CI, 1.23-2.51; P=.002) and compared with tremor before bradykinesia (HR, 1.75; 95% CI, 1.24-2.47; P=.001). Conclusion: Patients with tremor as a presenting symptom have longer survival. In contrast, the presence of bradykinesia/rigidity as a presenting symptom correlates with reduced survival across all types of synucleinopathies.
UR - http://www.scopus.com/inward/record.url?scp=85070307787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070307787&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2019.04.010
DO - 10.1016/j.mayocp.2019.04.010
M3 - Article
C2 - 31405749
AN - SCOPUS:85070307787
SN - 0025-6196
VL - 94
SP - 1825
EP - 1831
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 9
ER -